BEIJING BOHUI INNOVATION BIOTECHNOLOGY GROUP CO., LTD. Beijing Bohui Innovation Biotechnology Group Co., Ltd. Stock
Equities
300318
CNE000001QR4
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.88 CNY | -3.56% |
|
-4.13% | -21.79% |
| Sales 2021 | 715M 98.74M | Sales 2022 | 796M 110M | Capitalization | 4.78B 660M |
|---|---|---|---|---|---|
| Net income 2021 | -322M -44.48M | Net income 2022 | -78M -10.78M | EV / Sales 2021 | 12 x |
| Net Debt 2021 | 513M 70.91M | Net Debt 2022 | 674M 93.16M | EV / Sales 2022 | 6.85 x |
| P/E ratio 2021 |
-25.1
x | P/E ratio 2022 |
-61
x | Employees | 1,773 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 18.67% |
More Fundamentals
* Assessed data
More news
| 1 day | -3.56% | ||
| 1 week | -4.13% | ||
| Current month | -9.29% | ||
| 1 month | -0.81% | ||
| 3 months | -14.98% | ||
| 6 months | -14.83% | ||
| Current year | -21.79% |
1 week
4.50
5.44
1 month
4.506.19
Current year
3.436.39
1 year
3.436.93
3 years
3.4314.98
5 years
3.4323.80
10 years
3.4323.80
| Managers | Title | Age | Since |
|---|---|---|---|
Yan Jiang
CEO | Chief Executive Officer | 54 | 20-03-16 |
Hai Feng Dong
DFI | Director of Finance/CFO | 40 | 20-06-28 |
Jiang Hong Du
CHM | Chairman | 56 | 01-06-25 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jiang Hong Du
CHM | Chairman | 56 | 01-06-25 |
Jun Ban
BRD | Director/Board Member | 57 | 20-06-28 |
Zhi Wei Shen
CHM | Chairman | 46 | 22-05-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +1.04% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 4.88 | -3.56% | 12,824,500 |
| 24-04-17 | 5.06 | +3.90% | 18,977,630 |
| 24-04-16 | 4.87 | +4.96% | 21,686,450 |
| 24-04-15 | 4.64 | -5.11% | 10,825,680 |
| 24-04-12 | 4.89 | -3.93% | 10,816,530 |
End-of-day quote Shenzhen S.E., April 17, 2024
More quotes
Beijing Bohui Innovation Biotechnology Group Co Ltd, formerly Beijing Bohui Innovation Biotechnology Co Ltd, is a China-based company mainly engaged in inspection and testing business and blood products business. The Company operates two major reporting segments. The Inspection and Testing segment is mainly engaged in the research and development, production and sales of inspection instruments and inspection reagents. The Company's products for medical institutions mainly involve in vitro diagnostic testing, including human trace element testing and human papillomavirus (HPV) testing. The Company's testing equipment for non-medical institutions is mainly small mass spectrometers and related products. The Biological Products segment is mainly blood products, which can be divided into products such as albumin, immunoglobulin, coagulation factors and vaccines. The Company distributes its products within the domestic market and to overseas market.
Sector
Pharmaceuticals
Calendar
2024-04-25
- Q4 2023 Earnings Release
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -21.79% | 551M | |
| -6.19% | 84.46B | |
| +3.95% | 40.85B | |
| -26.37% | 27.69B | |
| +52.09% | 24.28B | |
| -6.59% | 17.09B | |
| -32.37% | 13.67B | |
| -10.45% | 11.79B | |
| -15.88% | 11.86B | |
| -2.85% | 8.07B |
- Stock Market
- Equities
- 300318 Stock
